Author: Customer Service

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company’s website. About Cronos Cronos is a global cannabis company focused on scaling leading consumer goods products through R&D and...

Marks Xtract One’s Fourth Canadian Provincial Health Authority Customer TORONTO, April 20, 2026 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”) today announced its SmartGateway has been selected by Health PEI, the agency delivering publicly-funded health services on Prince Edward Island, to support its ongoing commitment to patient, staff, and visitor safety across its numerous facilities. The phased rollout deployment will enable Health PEI to continue delivering on its commitment to providing safe, quality health care to all Islanders in today’s modern threat environment. As the organization responsible for hospitals, healthcare centers, long-term nursing facilities, and community-based health programs throughout the province, Health PEI plays a central role in advancing...

Order reflects growing adoption of lithium-based idle reduction systems across commercial heavy-duty trucking fleetsPurchase order valued at over $3 million from Stevens Transport, spanning nearly 500 trucks with deliveries throughout 2026. Order represents one of the largest and most comprehensive single-fleet adoptions of Dragonfly Energy’s heavy-duty trucking platform to date. Order spans the Company’s full heavy-duty trucking product portfolio and reflects the successful adoption progression from initial deployments to scaled, multi-system fleet implantation Order supports continued meaningful momentum in the commercial fleet segment, one of the Company’s key growth marketsRENO, Nev., April 20, 2026 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry...

Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preserved Identification of potential prognostic biomarkers upon further analyses of Phase 2 Bria-IMT™ study data Bria-OTS+™ in Preclinical Cancer Models to be presented on Tuesday April 21 from 2:00- 5:00 PM PST; Poster Number: 6701PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it is presenting positive data in three clinical posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting,...

James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children’s Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET WAYNE, Pa., April 20, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that two late-breaking abstracts highlighting results from the Phase 3 SELVA and Phase 2 TOIVA studies of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) were accepted for presentation at the International Society for the Study of...

VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) — Winshear Metals (TSX-V: WINS, FRA: 9HR) (“Winshear” or the “Company”) has granted 2,000,000 incentive stock options to directors, officers, employees and consultants of the Company. The options have an exercise price of $0.15 per share and expire on April 17, 2031. The options vest on a quarterly basis over the next 12 months. Winshear’s Stock Option Plan allows for the issuance of up to 10% of issued and outstanding share capital in the form of incentive stock options. As a result of this grant, the company has 5,700,000 options issued, representing 8.23% of the issued and outstanding share capital of the Company. Of the 2,000,000 options granted, 1,900,000 were granted to Directors and Officers of the Company. About Winshear Metals Corp. Winshear Metals Corp. is a...

HALIFAX, Nova Scotia, April 20, 2026 (GLOBE NEWSWIRE) — Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN; OTCQX: ERDCF) (“Erdene” or the “Company”) is pleased to provide a Bayan Khundii Gold Mine (“BK”) production update for Q1 2026, operated by Erdene Mongol LLC (“EM”), the Company’s joint venture with Mongolian Mining Corporation (“MMC”). All dollars are US unless otherwise noted. Peter Akerley, Erdene’s President and CEO stated, “During the first quarter of 2026 the Bayan Khundii gold mine achieved commercial production, realizing average throughput of nearly 90% of nameplate capacity. Gold recovery during the quarter averaged over 96%, exceeding projections in the most recent feasibility study. As we transition through ramp-up, we are delivering higher grade ore to the BK process plant.” Mr. Akerley...

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important opportunity in a key global market Agreement builds on TJ Biopharma’s development success of felzartamab in China and productive clinical collaboration in Biogen-led Phase 3 trials for IgAN and PMN since April 2025CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive rights to felzartamab...

SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet’s prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. “We are delighted to welcome Dr. Andreas Grauer to our executive leadership team as Chief Medical Officer. Dr. Grauer has an extensive track record in leading clinical development and medical affairs in global pharmaceutical organizations as well as an impressive academic career. His expertise and insights will be key as...

Proven healthcare growth leader to drive disciplined, profitable expansion and scale across Lumexa Imaging’s platform RALEIGH, N.C., April 20, 2026 (GLOBE NEWSWIRE) — Lumexa Imaging (NASDAQ: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced the appointment of Kyle Lynch as its new Chief Growth Officer (CGO). Lynch joins the executive leadership team to lead the company’s enterprise growth strategy, with responsibility for expanding Lumexa Imaging’s platform through joint ventures, acquisitions, and de novo development. In this role, Lynch will oversee the full growth lifecycle, including opportunity origination, transaction execution, and post-close value realization, with a focus on driving sustainable, profitable growth and maximizing return on invested capital. He will work closely with...